These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37578479)

  • 1. Synthesis and Radiolabeling of Glu-Urea-Lys with
    Hatamabadi D; Joukar S; Shakeri P; Balalaie S; Yazdani A; Khoramjouy M; Mazidi SM; Kobarfard F; Mosayebnia M; Bozorgchami N; Ahmadi M; Ayyoubzadeh SM; Shahhosseini S
    Cancer Biother Radiopharm; 2023 Sep; 38(7):486-496. PubMed ID: 37578479
    [No Abstract]   [Full Text] [Related]  

  • 2. Design, synthesis, radiolabeling and biological evaluation of new urea-based peptides targeting prostate specific membrane antigen.
    Mosayebnia M; Hajimahdi Z; Beiki D; Rezaeianpour M; Hajiramezanali M; Geramifar P; Sabzevari O; Amini M; Hatamabadi D; Shahhosseini S
    Bioorg Chem; 2020 Jun; 99():103743. PubMed ID: 32217372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical translation of a PSMA inhibitor for
    Ferro-Flores G; Luna-Gutiérrez M; Ocampo-García B; Santos-Cuevas C; Azorín-Vega E; Jiménez-Mancilla N; Orocio-Rodríguez E; Davanzo J; García-Pérez FO
    Nucl Med Biol; 2017 May; 48():36-44. PubMed ID: 28193503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel technetium-99m-labeled bivalent PSMA-targeting probe based on hydroxamamide chelate for diagnosis of prostate cancer.
    Shimizu Y; Ando M; Watanabe H; Ono M
    Ann Nucl Med; 2024 Oct; 38(10):847-851. PubMed ID: 38976087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
    Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
    J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and SAR of ⁹⁹mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates.
    Lu G; Maresca KP; Hillier SM; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1557-63. PubMed ID: 23333070
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Xu X; Zhang J; Hu S; He S; Bao X; Ma G; Luo J; Cheng J; Zhang Y
    Nucl Med Biol; 2017 May; 48():69-75. PubMed ID: 28273495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hybrid Tracers Based on Cyanine Backbones Targeting Prostate-Specific Membrane Antigen: Tuning Pharmacokinetic Properties and Exploring Dye-Protein Interaction.
    Hensbergen AW; Buckle T; van Willigen DM; Schottelius M; Welling MM; van der Wijk FA; Maurer T; van der Poel HG; van der Pluijm G; van Weerden WM; Wester HJ; van Leeuwen FWB
    J Nucl Med; 2020 Feb; 61(2):234-241. PubMed ID: 31481575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA).
    Ray Banerjee S; Pullambhatla M; Foss CA; Falk A; Byun Y; Nimmagadda S; Mease RC; Pomper MG
    J Med Chem; 2013 Aug; 56(15):6108-21. PubMed ID: 23799782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation and Biological Evaluation of [
    Xiao D; Duan X; Gan Q; Zhang X; Zhang J
    Molecules; 2020 Nov; 25(23):. PubMed ID: 33256058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of (99m)Tc-labeled asymmetric urea derivatives that target prostate-specific membrane antigen for single-photon emission computed tomography imaging.
    Kimura H; Sampei S; Matsuoka D; Harada N; Watanabe H; Arimitsu K; Ono M; Saji H
    Bioorg Med Chem; 2016 May; 24(10):2251-6. PubMed ID: 27073053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and Evaluation of
    Lu K; Zhang C; Zhang Z; Kuo HT; Colpo N; Bénard F; Lin KS
    Molecules; 2023 Jun; 28(13):. PubMed ID: 37446782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
    Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
    Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and evaluation of new mixed "2 + 1" Re,
    Shegani A; Ischyropoulou M; Roupa I; Kiritsis C; Makrypidi K; Papasavva A; Raptopoulou C; Psycharis V; Hennkens HM; Pelecanou M; Papadopoulos MS; Pirmettis I
    Bioorg Med Chem; 2021 Oct; 47():116373. PubMed ID: 34467870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA).
    Banerjee SR; Foss CA; Castanares M; Mease RC; Byun Y; Fox JJ; Hilton J; Lupold SE; Kozikowski AP; Pomper MG
    J Med Chem; 2008 Aug; 51(15):4504-17. PubMed ID: 18637669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a New
    Farahani AM; Maleki F; Sadeghzadeh N; Abediankenari S; Abedi SM; Erfani M
    Anticancer Agents Med Chem; 2020; 20(14):1695-1703. PubMed ID: 32560611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
    Robu S; Schottelius M; Eiber M; Maurer T; Gschwend J; Schwaiger M; Wester HJ
    J Nucl Med; 2017 Feb; 58(2):235-242. PubMed ID: 27635024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake.
    Kuo HT; Lin KS; Zhang Z; Zhang C; Merkens H; Tan R; Roxin A; Uribe CF; Bénard F
    Theranostics; 2022; 12(14):6179-6188. PubMed ID: 36168623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
    Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
    J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of
    Pham TT; Hungnes IN; Rivas C; Cleaver J; Firth G; Blower PJ; Sosabowski J; Cook GJR; Livieratos L; Young JD; Pringle PG; Ma MT
    J Nucl Med; 2024 Jul; 65(7):1087-1094. PubMed ID: 38844360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.